Overview
Aytu is committed to improving the health of all children. Our portfolio of products with a focus on ADHD help children live their best lives. Aytu is also developing potentially life-saving products by investing in a near-term pipeline of breakthrough treatments focused on pediatric-onset, rare diseases. Follow us on our journey.
Leadership
Decades of experience with a focus on better health today.
The Aytu BioPharma leadership team is as unique as our portfolio of products. Our experience spans decades, but we never stop thinking about the future.
Management Team
Josh Disbrow
Chairman & Chief Executive Officer
Bio 
Mark Oki
Chief Financial Officer
Bio
Greg Pyszczymuka
Chief Commercial Officer
Bio
Jarrett Disbrow
Executive Vice President, Corporate Operations
Bio
Topher Brooke
Executive Vice President, Rare Disease Development
Bio
Russ McMahen
Senior Vice President of Research & Development
Bio
Vice President of Operations
Bio
Vice President of Regulatory Affairs and Quality Assurance
Bio
Board of Directors
Josh Disbrow
Chairman & Chief Executive Officer
Bio
Gary Cantrell
Director
Bio
John Donofrio, Jr.
Director, Chair, Audit Committee
Bio
Carl Dockery
Director & Chair, Nominating & Governance Committee
Bio
Vivian Liu
Director
Bio
Michael Macaluso
Director, Chair, Compensation Committee
Bio
Our Mission & Vision
We aspire to be the leading pediatric-focused pharmaceutical company in the world. We will achieve this by commercializing novel therapeutics, providing best-in-class patient access, unleashing the talents of our people, and developing important and needed therapeutics for children of all ages.
- We will make a lasting difference in children’s lives by delivering the best products to children in need.
- Our individual actions, collective attitude, and company results will inspire others to do great things.
- Our people, products, pipeline, and platform will effect positive change in healthcare delivery and patient outcomes.
Supporting our Communities
At Aytu we strive to make a positive impact on children through our product offerings, the development of our innovative pipeline, and the actions of our outstanding people. We are active in our communities and support the work of various organizations that work on behalf of the patients we aim to serve, the children in our communities, and our corporate ecosystem.
We are a corporate partner to several leading patient advocacy organizations supporting Vascular Ehlers-Danlos Syndrome (VEDS) patients and their caregivers. We are engaged with and support Annabelle’s Challenge, Defy Foundation, The Ehlers-Danlos Society, FIGHT vEDS, and The VEDS Movement. We are also corporate sponsors of each organization’s programs.
Annabelle’s Challenge is the leading charity providing support to patients and families touched by Vascular Ehlers-Danlos Syndrome (Vascular EDS) across the UK and globally. They are also proud recipients of The Queen’s Award for Voluntary Service.
The DEFY Foundation is committed to finding a cure and defying Vascular Ehlers-Danlos Syndrome.
The Ehlers-Danlos Society is dedicated to saving and improving the lives of those affected worldwide by the Ehlers-Danlos syndromes (EDS), hypermobility spectrum disorders (HSD), and related symptoms and conditions.
FIGHT vEDS is a non-profit organization dedicated to fighting and finding a treatment for vascular Ehlers-Danlos Syndrome. Their three core initiatives include bringing up-to-date information to patients, promoting low-cost genetic testing, and advancing research.
The VEDS Movement mission is to save lives and improve the quality of life of individuals with Vascular Ehlers-Danlos Syndrome (VEDS).
We are active in the Colorado life sciences and biotechnology ecosystem and are corporate members of the Colorado BioScience Association. We actively advocate for and support the work of our life science corporate neighbors.